LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

Overall Survival(OS)

Overall survival was assessed as a secondary objective.3

  • There was no statistically significant difference in OS between the two arms in the BRCAm population.35
  • In the BRCAm population there was a numerical difference of a median of 4.7 months in favour of Lynparza (HR 0.62; 95% CI 0.41-0.94; p=0.025; median 34.9 months Lynparza vs 30.2 months placebo).35
A comparison chart between Placebo and Lynparza about OS
A comparison chart between Placebo and Lynparza about OS

Adapted with permission from Ledermann.35

Long term exposure to treatment

15% of patients with a BRCA mutation remain on Lynparza at 5 years vs. 2% of patients on placebo supporting the long-term benefit and tolerability of this treatment.35

At 5 years, 15% of patients with a BRCAm were still taking Lynparza
At 5 years, 15% of patients with a BRCAm were still taking Lynparza